Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,558 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma.
Hoshi Y, Enokida T, Tamura S, Nakashima T, Okano S, Fujisawa T, Sato M, Wada A, Tanaka H, Takeshita N, Tanaka N, Onaga R, Kishida T, Uryu H, Sakashita S, Asakage T, Tahara M. Hoshi Y, et al. Among authors: nakashima t. Front Oncol. 2024 May 23;14:1379013. doi: 10.3389/fonc.2024.1379013. eCollection 2024. Front Oncol. 2024. PMID: 38846982 Free PMC article.
Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma.
Hashimoto K, Yasumatsu R, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T. Hashimoto K, et al. Among authors: nakashima t. Anticancer Res. 2022 Feb;42(2):981-989. doi: 10.21873/anticanres.15558. Anticancer Res. 2022. PMID: 35093898
Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer.
Nakano T, Yasumatsu R, Hashimoto K, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T. Nakano T, et al. Among authors: nakashima t. In Vivo. 2022 Mar-Apr;36(2):979-984. doi: 10.21873/invivo.12790. In Vivo. 2022. PMID: 35241559 Free PMC article.
Japanese Clinical Practice Guideline for Head and Neck Cancer.
Nibu KI, Hayashi R, Asakage T, Ojiri H, Kimata Y, Kodaira T, Nagao T, Nakashima T, Fujii T, Fujii H, Homma A, Matsuura K, Monden N, Beppu T, Hanai N, Kirita T, Kamei Y, Otsuki N, Kiyota N, Zenda S, Omura K, Omori K, Akimoto T, Kawabata K, Kishimoto S, Kitano H, Tohnai I, Nakatsuka T. Nibu KI, et al. Among authors: nakashima t. Auris Nasus Larynx. 2017 Aug;44(4):375-380. doi: 10.1016/j.anl.2017.02.004. Epub 2017 Mar 18. Auris Nasus Larynx. 2017. PMID: 28325607 Review.
Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2).
Yokota T, Ota Y, Fujii H, Kodaira T, Shimokawa M, Nakashima T, Monden N, Homma A, Ueda S, Akimoto T. Yokota T, et al. Among authors: nakashima t. Int J Clin Oncol. 2021 Feb;26(2):316-325. doi: 10.1007/s10147-020-01817-4. Epub 2020 Oct 30. Int J Clin Oncol. 2021. PMID: 33125596
Japanese Board Certification System for head and neck surgeons.
Yoshimoto S, Nakashima T, Fujii T, Matsuura K, Otsuki N, Asakage T, Fujimoto Y, Hanai N, Homma A, Monden N, Okami K, Sugasawa M, Hasegawa Y, Nibu K, Kamata SE, Kishimoto S, Kohno N, Fukuda S, Hisa Y. Yoshimoto S, et al. Among authors: nakashima t. Auris Nasus Larynx. 2014 Aug;41(4):327-30. doi: 10.1016/j.anl.2013.10.019. Epub 2014 Feb 26. Auris Nasus Larynx. 2014. PMID: 24581685
2,558 results